Draft Guidance for Industry on Qualification Process for Drug Development Tools; Availability
Document ID: FDA-2010-D-0529-0001
Comments
Total: 15
-
Novo Nordisk Inc. - Comment
Posted : 01/18/2011 ID ：FDA-2010-D-0529-0003 Agency : FDA -
Jan 24,2011 11:59 PM ET
-
AstraZeneca - Comment
Posted : 01/18/2011 ID ：FDA-2010-D-0529-0004 Agency : FDA -
Jan 24,2011 11:59 PM ET
-
MedImmune, LLC - Comment
Posted : 01/31/2011 ID ：FDA-2010-D-0529-0006 Agency : FDA -
Jan 24,2011 11:59 PM ET
-
Amgen, Inc. - Comment
Posted : 01/31/2011 ID ：FDA-2010-D-0529-0007 Agency : FDA -
Jan 24,2011 11:59 PM ET
-
Bausch+Lomb - Comment
Posted : 01/31/2011 ID ：FDA-2010-D-0529-0008 Agency : FDA -
Jan 24,2011 11:59 PM ET
-
Quintiles - Comment
Posted : 01/31/2011 ID ：FDA-2010-D-0529-0009 Agency : FDA -
Jan 24,2011 11:59 PM ET
-
International Society for CNS Clinical Trials and Methodology (ISCTM) - Comment
Posted : 01/31/2011 ID ：FDA-2010-D-0529-0010 Agency : FDA -
Jan 24,2011 11:59 PM ET
-
Hyman, Phelps & McNamara, P.C. (CORAR/MICAA) - Comment
Posted : 01/31/2011 ID ：FDA-2010-D-0529-0011 Agency : FDA -
Jan 24,2011 11:59 PM ET
-
Pharmaceutical Research and Manufacturers of America (PhRMA) - Comment
Posted : 01/31/2011 ID ：FDA-2010-D-0529-0013 Agency : FDA -
Jan 24,2011 11:59 PM ET
-
Alliance for Regenerative Medicine - Comment
Posted : 01/31/2011 ID ：FDA-2010-D-0529-0015 Agency : FDA -
Jan 24,2011 11:59 PM ET
-
Life Technologies - Comment
Posted : 01/31/2011 ID ：FDA-2010-D-0529-0016 Agency : FDA -
Jan 24,2011 11:59 PM ET
-
Biotechnology Industry Organization (BIO) - Comment
Posted : 01/31/2011 ID ：FDA-2010-D-0529-0017 Agency : FDA -
Jan 24,2011 11:59 PM ET
-
Critical Path Institute - Comment
Posted : 01/31/2011 ID ：FDA-2010-D-0529-0018 Agency : FDA -
Jan 24,2011 11:59 PM ET
-
Bayer HealthCare - Comment
Posted : 01/31/2011 ID ：FDA-2010-D-0529-0019 Agency : FDA -
Jan 24,2011 11:59 PM ET
-
Forest Research Institute, Inc. - Comment
Posted : 02/28/2011 ID ：FDA-2010-D-0529-0020 Agency : FDA -
Jan 24,2011 11:59 PM ET